Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Squamous Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Squamous Cell Neoplasm

Cancer Family

Squamous Cell Neoplasm

CI-CAN-00000359Explore in graph →

Non-malignant1,024 active trials9 approved drugs78 evidence items

NCIt: C3792
MeSH: D018307

Overview
Statistics
Survival
Genomics26
Variants & evidence78
Drugs35
Trials3210
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (75)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 75 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.
· J Natl Cancer Inst · 1998 · PMID 9625170 · validated civic_curation pubmed
The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
· Clin Transl Oncol · 2016 · PMID 26459251 · validated civic_curation pubmed
p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.
· J Clin Oncol · 2014 · PMID 25267748 · validated civic_curation pubmed
Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
· Clin Cancer Res · 2011 · PMID 21653686 · validated civic_curation pubmed
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
· Ann Oncol · 2014 · PMID 25081901 · validated civic_curation pubmed
Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma.
· Mol Cancer · 2015 · PMID 26634247 · validated civic_curation pubmed
HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas.

Showing 26–50 of 75 publications

← Previous
1
2
3
Next →

· J Clin Invest · 2013 · PMID 23635773 · validated civic_curation pubmed

Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection.

· PLoS One · 2016 · PMID 27414035 · validated civic_curation pubmed

Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma.

· BMC Cancer · 2015 · PMID 25924824 · validated civic_curation pubmed

Mutational landscape of aggressive cutaneous squamous cell carcinoma.

· Clin Cancer Res · 2014 · PMID 25303977 · validated civic_curation pubmed

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

· J Clin Oncol · 2017 · PMID 27870574 · validated civic_curation pubmed

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.

· J Exp Med · 2019 · PMID 30683736 · validated civic_curation pubmed

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

· Clin Cancer Res · 2023 · PMID 36806911 · validated civic_curation pubmed

p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.

· Oral Oncol · 2014 · PMID 24239278 · validated civic_curation pubmed

Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma.

· J Oral Pathol Med · 2006 · PMID 16454808 · validated civic_curation pubmed

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

· Lancet Oncol · 2015 · PMID 25892145 · validated civic_curation pubmed

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.

· J Clin Oncol · 2021 · PMID 33750196 · validated civic_curation pubmed

Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.

· Target Oncol · 2016 · PMID 26115874 · validated civic_curation pubmed

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

· JAMA Oncol · 2015 · PMID 26181029 · validated civic_curation pubmed

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant.

· Cold Spring Harb Mol Case Stud · 2020 · PMID 31871216 · validated civic_curation pubmed

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

· Cancer Discov · 2011 · PMID 22328973 · validated civic_curation pubmed

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.

· J Clin Oncol · 2016 · PMID 24934779 · validated civic_curation pubmed

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.

· Cancer Res · 2013 · PMID 23786770 · validated civic_curation pubmed

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

· Lung Cancer · 2014 · PMID 24192513 · validated civic_curation pubmed

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

· Clin Cancer Res · 2016 · PMID 26787751 · validated civic_curation pubmed